Goldline Pharmaceutical Ltd IPO
Status: Closed
Overview
IPO date
12 May 2026 to 14 May 2026
Face value
₹ 10 per share
Price
₹ 41 to ₹43 per share
Issue Size
2,700,000 shares
(aggregating up to ₹ 11.61 Cr)
(aggregating up to ₹ 11.61 Cr)
Allotment Date
15 May 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Pharmaceuticals
Objectives of Goldline Pharmaceutical Ltd IPO
Goldline Pharmaceutical Ltd IPO Strategy
About Goldline Pharmaceutical Ltd
Unlock Stock of the Month
T&C*
Strengths vs Risks of Goldline Pharmaceutical Ltd
Know the pros & cons
Strengths
Experienced promoters and management team with industry knowledge and a track record.- Asset-light business model and competitive products.
- Scalable Business Model.
- Wide and diverse range of product offerings.
- Strong Supplier and Vendor Relationships.
- Established Distribution Network.
Risks
- Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products,
and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements
could adversely affect its business, results of operations and financial condition.
- The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting
in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in
the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no
assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays
will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the
Company or its directors/officers, it could negatively affect the Company's business and financial condition.
- The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical
products, failure of which may has an adverse impact on its revenue and profitability.
- There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay
in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties
on it or take certain punitive actions against the Company in relation to the same which may has adverse impact
on its business, financial condition and results of operations.
- Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from
any one of the company key intermediaries may adversely affect its business and results of operations. the Company has
a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its
revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their
demand for the company products, its business, results of operations and financial condition will be materially and
adversely affected.
- There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel,
Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
- The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and
Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and
may compete with it.
- Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such
products declines in the future, or if the company unable to sell such products for any reason, its business, financial
condition, cash flows and results of operations could be adversely affected.
- The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of
customers for the company revenue from operations.
- The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash
flow could impact its growth and business.
- The company earn a certain portion of its revenue from three of the company Promoter Group entities, namely, Nucleage Pharma Solutions Private Limited, Activista Healthcare Private Limited and Numerius Healthcare Private Limited.
Accordingly, its dependent upon them to market and sell the company products.
- Its business and prospect may be adversely affected if the company unable to maintain and grow the image of its brands.
- A part of the Net Proceeds will be utilized for the repayment of indebtedness availed of by the Company. Accordingly, the utilization of the Net Proceeds will not result in creation of any tangible assets.
- The company inability to effectively manage or expand its distribution network may has an adverse effect on its business,
results of operations and financial condition.
- The company has not been able to trace certain historical bank statements related to past allotments, and any inability to
furnish such records in the future may expose it to regulatory scrutiny.
- If the company unable to anticipate and respond to changes in the market trends and changing customer preferences in
a timely and effective manner, or if its fail to maintain the company reputation, brand value or increase the market for the company products, the demand for its products may decline.
- The company inability to obtain, renew or maintain our statutory and regulatory permits and approvals required to operate
the company business may has a material adverse effect on its business, financial condition and results of operations.
- The company business largely depends on the performance of its marketing team. Any non-performance by the company marketing team to market its products before the medical professionals, may adversely affect the company business operations, profitability and cash flows.
- The company insurance coverage may not be adequate to cover all losses or liabilities that its may incur in the company business and operations.
- The company rely on third-party transportation providers for procurement of its products and for supply of the company products and failure by any of its transportation providers could result in loss in sales.
- The Company has not recognized interest on delayed payments to MSME creditors and may be required to create provisions towards such interest, which could adversely affect its financials.
- The Company has previously operated from certain promoter-owned premises without formal leave and license agreements, which has now been regularized.
- If the company or its distributors are unable to collect the company dues and receivables from end users, its results of operations and cash flows could be adversely affected.
- The company operations are subject to high working capital requirements. Its inability to maintain an optimal level of
working capital required for the company business may impact its operations adversely.
- Its may not be able to correctly assess the demand for the company products, which may adversely affect its business,
financial condition and results of operations.
- The company may be unable to grow its business in additional geographic regions, which may adversely affect the company business prospects and results of operations.
- If the company fail to maintain an effective system of internal controls, its may not be able to successfully manage, or
accurately report, the company financial risks.
- Its funding requirements and the proposed deployment of Net Proceeds are not appraised by any independent
agency, which may affect the company business and results of operations.
- All of its premises, including the company Registered Office and go down are not owned by it and the company has only leasehold or leave and license rights over them. In the event its lose such rights, t business, financial condition and results
of operations and cash flows could be adversely affected.
- Its may not be successful in implementing the company business strategies.
- The company rely extensively on its operational support systems, including on the company information technology systems in
managing its supply chain, procurement process, logistics and other integral parts of the company business, failure of
which could adversely affect its business, financial conditions and results of operations.
- Its subject to stringent regulation and any adverse regulatory action may materially adversely affect the company
financial condition and business operations.
- The company results of operations are likely to vary from year to year and be unpredictable, which could cause the market
price of the Equity Shares to be volatile.
- Product liability and other civil claims and costs incurred as a result of product recalls could has a material adverse effect on its business.
- If the company inadvertently infringe on the patents of others, its business may be adversely affected.
- The company face intense competition and may not be able to keep pace with the rapid technological changes in the
pharmaceutical industry.
- Its may not be able to maintain the company current levels of profitability due to increased costs or reduced trading spreads
or margins.
- Its Promoters, Directors, Key Managerial Personnel and Senior Management has interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
- Any adverse change in regulations governing its products and the products of the company customers, may adversely
impact its business prospects and results of operations.
- The company Promoters and members of the Promoter Group has significant control over the Company and has the
ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.
- The average cost of acquisition of Equity Shares held by Its Promoters could be lower than the Issue Price.
- The company future fund requirements, in the form of further issue of capital or securities and/or loans taken by it, may
be prejudicial to the interest of the Shareholders depending upon the terms on which they are eventually raised.
- The company has in past entered into related party transactions and we may continue to does so in the future.
- The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue.
Further, the company has not identified any alternate source of financing the `Objects of the Issue. Any shortfall in raising
/ meeting the same could adversely affect the company growth plans, operations and financial performance.
- The company financing agreements with lenders contain restrictive covenants which may limit its operational flexibility.
Further, in the absence of no-objection certificates ("NOCs") from such lenders, the company ability to undertake certain
corporate actions may be restricted.
- The Company has availed certain unsecured loans from third parties, which are re callable in nature.
- The company success largely depends upon the knowledge and experience of its Promoters, Directors, the company Key Managerial Personnel and its Senior Management. Loss of any of the company Directors and key managerial personnel or the company ability to attract and retain them could adversely affect its business, operations and financial condition.
- The availability of lookalikes, counterfeit healthcare products manufactured by other companies and passed off
as its products, could adversely affect the company goodwill and results of operations.
- There is no monitoring agency appointed by the Company and the deployment of funds is at the discretion of the company
Management and its Board of Directors, though it shall be monitored by the company Audit Committee.
- Any variation in the utilization of the Net Proceeds as disclosed in this Red Herring Prospectus shall be subject to
certain compliance requirements, including prior Shareholders' approval.
- In addition to the company existing indebtedness for its existing operations, the company may incur further indebtedness during the course of business. its cannot assure that the company would be able to service its existing and/ or additional indebtedness.
- Its Promoters are co-borrowers to certain unsecured loans availed by the Company. In event of default of the debt obligations, its Promoters will has to bear the liability, which may adversely affect the Promoter's ability to manage the affairs of the Company.
- Its Promoters, one of the members of the company Promoter Group and their relatives has extended personal guarantees
with respect to loan facilities availed by the Company. Further, Promoters and members of its Promoter Group
has provided their property as collateral security for loan facilities availed by the Company. Revocation of any
or all of these personal guarantees or withdrawal of such property may adversely affect its business operations
and financial condition.
- Its ability to pay dividends in the future may be affected by any material adverse effect on the company future earnings,
financial condition or cash flows.
- The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could
adversely affect its financial condition, results of operations and reputation.
- The company has not independently verified certain data in this Red Herring Prospect it.
- The requirements of being a listed company may strain the company resources.
- The Equity Shares has never been publicly traded and the Issue may not result in an active or liquid market for the Equity Shares.
- There is no guarantee that the Equity Shares offered pursuant to the Issue will be listed on the SME Platform of
BSE Limited in a timely manner or at all.
- There is no existing market for the company Equity Shares, and its does not know if one will develop to provide you with
adequate liquidity. Further, an active trading market for the Equity Shares may not develop and the price of the
Equity Shares may be volatile.
- The price of the Equity Shares may be highly volatile after the Issue, which could result in substantial losses for
investors acquiring the Equity Shares in the Issue.
- Sale of Equity Shares by its Promoters or Other Significant Shareholders May Adversely Affect the Trading Price
of the company Equity Shares
- Potential risks arising from the independent distribution and C&F businesses of Promoter Group entities and any perceived overlap or diversion of business opportunities.
- You will not be able to sell immediately on the Stock Exchange any of the Equity Shares you purchase in the Issue.
- Failure to Effectively Implement the company Business Strategies Could Adversely Affect its Business, Financial
Condition and Results of Operations.
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a
shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in
time.
- Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by the Company
may dilute your shareholding and any sale of Equity Shares by its Promoters or members of the company Promoters Group
may adversely affect the trading price of the Equity Shares.
- Any of the Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the
Bid Amount) at any stage after submitting a Bid.
- Sale of Equity Shares by its Promoters or other significant shareholder(s) may adversely affect the trading price
of the Equity Shares.
Goldline Pharmaceutical Ltd Peer Comparison
Understand the company’s industry standing
Goldline Pharmaceutical Limited
Mono Pharmacare Limited
Chandra Bhagat Pharma Limited
Face Value
10
10
10
Standalone / Consolidated
Standalone
Consolidated
Consolidated
Total Income Rs. Cr.
28.06
168.34
86.72
EPS-Basis
4.1
1.75
1.14
EPS-Diluted
4.1
1.75
1.14
NAV Per Share
12.38
17.66
39.72
P/E-Basic EPS
---
7.57
28.94
P/E-Diluted EPS
---
---
---
RONW(%)
27.37
9.9
2.86
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Goldline Pharmaceutical Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 12 May 2026 & closes on 14 May 2026.
Goldline Pharmaceutical Limited was originally incorporated on August 2, 2004, as a private limited Company in the name of Goldline Pharmaceutical Private Limited' with the Registrar of Companies, Mumbai. Subsequently, Company was converted into a public limited Company and the name of Company was changed to Goldline Pharmaceutical Limited' w.e.f. September 23, 2013.
Company is engaged in the business of marketing pharmaceutical products under the Goldline brand. Their products are divided into five categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Valiente. The pharmaceutical products marketed under the 'Goldline' brand are not manufactured by Company. Instead, they enter into contractual arrangements with third-party manufacturers, who produce the products based on market research, demand analysis, and specifications. Presently, Company maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.
Company extend comprehensive material supply and procurement support to hospitals and healthcare partners. Through the promoter group entities as Numerius Healthcare Pvt Ltd & Activista Healthcare Pvt Ltd, Company manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.
Company is planning the Initial Public Offer of 30,00,000 Equity Shares having the face value of Rs 10 each through Fresh Issue.
Goldline Pharmaceutical Ltd IPO will close on 14 May 2026.
- Experienced promoters and management team with industry knowledge and a track record.
- Asset-light business model and competitive products.
- Scalable Business Model.
- Wide and diverse range of product offerings.
- Strong Supplier and Vendor Relationships.
- Established Distribution Network.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Amol Laxmikant Mujumdar | 2749988 | 39.85 | 2749988 | 28.65 |
| 2 | Swapan Premprakash Khandelwal | 2749988 | 39.85 | 2749988 | 28.65 |
| 3 | Asha Swapan Khandelwal | 3 | --- | 3 | --- |
| 4 | Aishwarya Amol Mujumdar | 3 | --- | 3 | --- |
- Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
- The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
- The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
- There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
- Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
- There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
- The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and may compete with it.
- Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such products declines in the future, or if the company unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
- The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of customers for the company revenue from operations.
- The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
- The company earn a certain portion of its revenue from three of the company Promoter Group entities, namely, Nucleage Pharma Solutions Private Limited, Activista Healthcare Private Limited and Numerius Healthcare Private Limited. Accordingly, its dependent upon them to market and sell the company products.
- Its business and prospect may be adversely affected if the company unable to maintain and grow the image of its brands.
- A part of the Net Proceeds will be utilized for the repayment of indebtedness availed of by the Company. Accordingly, the utilization of the Net Proceeds will not result in creation of any tangible assets.
- The company inability to effectively manage or expand its distribution network may has an adverse effect on its business, results of operations and financial condition.
- The company has not been able to trace certain historical bank statements related to past allotments, and any inability to furnish such records in the future may expose it to regulatory scrutiny.
- If the company unable to anticipate and respond to changes in the market trends and changing customer preferences in a timely and effective manner, or if its fail to maintain the company reputation, brand value or increase the market for the company products, the demand for its products may decline.
- The company inability to obtain, renew or maintain our statutory and regulatory permits and approvals required to operate the company business may has a material adverse effect on its business, financial condition and results of operations.
- The company business largely depends on the performance of its marketing team. Any non-performance by the company marketing team to market its products before the medical professionals, may adversely affect the company business operations, profitability and cash flows.
- The company insurance coverage may not be adequate to cover all losses or liabilities that its may incur in the company business and operations.
- The company rely on third-party transportation providers for procurement of its products and for supply of the company products and failure by any of its transportation providers could result in loss in sales.
- The Company has not recognized interest on delayed payments to MSME creditors and may be required to create provisions towards such interest, which could adversely affect its financials.
- The Company has previously operated from certain promoter-owned premises without formal leave and license agreements, which has now been regularized.
- If the company or its distributors are unable to collect the company dues and receivables from end users, its results of operations and cash flows could be adversely affected.
- The company operations are subject to high working capital requirements. Its inability to maintain an optimal level of working capital required for the company business may impact its operations adversely.
- Its may not be able to correctly assess the demand for the company products, which may adversely affect its business, financial condition and results of operations.
- The company may be unable to grow its business in additional geographic regions, which may adversely affect the company business prospects and results of operations.
- If the company fail to maintain an effective system of internal controls, its may not be able to successfully manage, or accurately report, the company financial risks.
- Its funding requirements and the proposed deployment of Net Proceeds are not appraised by any independent agency, which may affect the company business and results of operations.
- All of its premises, including the company Registered Office and go down are not owned by it and the company has only leasehold or leave and license rights over them. In the event its lose such rights, t business, financial condition and results of operations and cash flows could be adversely affected.
- Its may not be successful in implementing the company business strategies.
- The company rely extensively on its operational support systems, including on the company information technology systems in managing its supply chain, procurement process, logistics and other integral parts of the company business, failure of which could adversely affect its business, financial conditions and results of operations.
- Its subject to stringent regulation and any adverse regulatory action may materially adversely affect the company financial condition and business operations.
- The company results of operations are likely to vary from year to year and be unpredictable, which could cause the market price of the Equity Shares to be volatile.
- Product liability and other civil claims and costs incurred as a result of product recalls could has a material adverse effect on its business.
- If the company inadvertently infringe on the patents of others, its business may be adversely affected.
- The company face intense competition and may not be able to keep pace with the rapid technological changes in the pharmaceutical industry.
- Its may not be able to maintain the company current levels of profitability due to increased costs or reduced trading spreads or margins.
- Its Promoters, Directors, Key Managerial Personnel and Senior Management has interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
- Any adverse change in regulations governing its products and the products of the company customers, may adversely impact its business prospects and results of operations.
- The company Promoters and members of the Promoter Group has significant control over the Company and has the ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.
- The average cost of acquisition of Equity Shares held by Its Promoters could be lower than the Issue Price.
- The company future fund requirements, in the form of further issue of capital or securities and/or loans taken by it, may be prejudicial to the interest of the Shareholders depending upon the terms on which they are eventually raised.
- The company has in past entered into related party transactions and we may continue to does so in the future.
- The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue. Further, the company has not identified any alternate source of financing the `Objects of the Issue. Any shortfall in raising / meeting the same could adversely affect the company growth plans, operations and financial performance.
- The company financing agreements with lenders contain restrictive covenants which may limit its operational flexibility. Further, in the absence of no-objection certificates ("NOCs") from such lenders, the company ability to undertake certain corporate actions may be restricted.
- The Company has availed certain unsecured loans from third parties, which are re callable in nature.
- The company success largely depends upon the knowledge and experience of its Promoters, Directors, the company Key Managerial Personnel and its Senior Management. Loss of any of the company Directors and key managerial personnel or the company ability to attract and retain them could adversely affect its business, operations and financial condition.
- The availability of lookalikes, counterfeit healthcare products manufactured by other companies and passed off as its products, could adversely affect the company goodwill and results of operations.
- There is no monitoring agency appointed by the Company and the deployment of funds is at the discretion of the company Management and its Board of Directors, though it shall be monitored by the company Audit Committee.
- Any variation in the utilization of the Net Proceeds as disclosed in this Red Herring Prospectus shall be subject to certain compliance requirements, including prior Shareholders' approval.
- In addition to the company existing indebtedness for its existing operations, the company may incur further indebtedness during the course of business. its cannot assure that the company would be able to service its existing and/ or additional indebtedness.
- Its Promoters are co-borrowers to certain unsecured loans availed by the Company. In event of default of the debt obligations, its Promoters will has to bear the liability, which may adversely affect the Promoter's ability to manage the affairs of the Company.
- Its Promoters, one of the members of the company Promoter Group and their relatives has extended personal guarantees with respect to loan facilities availed by the Company. Further, Promoters and members of its Promoter Group has provided their property as collateral security for loan facilities availed by the Company. Revocation of any or all of these personal guarantees or withdrawal of such property may adversely affect its business operations and financial condition.
- Its ability to pay dividends in the future may be affected by any material adverse effect on the company future earnings, financial condition or cash flows.
- The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
- The company has not independently verified certain data in this Red Herring Prospect it.
- The requirements of being a listed company may strain the company resources.
- The Equity Shares has never been publicly traded and the Issue may not result in an active or liquid market for the Equity Shares.
- There is no guarantee that the Equity Shares offered pursuant to the Issue will be listed on the SME Platform of BSE Limited in a timely manner or at all.
- There is no existing market for the company Equity Shares, and its does not know if one will develop to provide you with adequate liquidity. Further, an active trading market for the Equity Shares may not develop and the price of the Equity Shares may be volatile.
- The price of the Equity Shares may be highly volatile after the Issue, which could result in substantial losses for investors acquiring the Equity Shares in the Issue.
- Sale of Equity Shares by its Promoters or Other Significant Shareholders May Adversely Affect the Trading Price of the company Equity Shares
- Potential risks arising from the independent distribution and C&F businesses of Promoter Group entities and any perceived overlap or diversion of business opportunities.
- You will not be able to sell immediately on the Stock Exchange any of the Equity Shares you purchase in the Issue.
- Failure to Effectively Implement the company Business Strategies Could Adversely Affect its Business, Financial Condition and Results of Operations.
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in time.
- Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by the Company may dilute your shareholding and any sale of Equity Shares by its Promoters or members of the company Promoters Group may adversely affect the trading price of the Equity Shares.
- Any of the Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid.
- Sale of Equity Shares by its Promoters or other significant shareholder(s) may adversely affect the trading price of the Equity Shares.
The Issue type of Goldline Pharmaceutical Ltd is Book Building - SME.
The minimum application for shares of Goldline Pharmaceutical Ltd is 6000.
The total shares issue of Goldline Pharmaceutical Ltd is 2700000.
Initial public offer of upto 27,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Goldline Pharmaceutical Limited ("Issuer" or "The" "company") at an issue price of Rs. 43 per equity share (including a share premium of Rs.33 per equity share) for cash, aggregating up to Rs. 11.61 Crores ("Public Issue") out of which 1,38,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating Rs. 0.59 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 25,62,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating up to Rs. 11.02 Crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 28.13% and 26.69% respectively of the post-issue paid-up equity share capital of the company.
Price Band is Rs. 43 per equity share of face value of Rs. 10/- each.
The floor price is 4.3 times of the face value.
Bids can be made for a minimum of Two lot and in multiples of 3,000 equity shares thereafter.